Article Sidebar
Published:
Apr 10, 2019Keywords:
Hydroxyurea; thrombocytosis; splenectomy
Article Details
Issue
Section
Articles
Brief summary of the agreement
Anyone is free:
· to copy, distribute, and display the work;
· to make derivative works;
· to make commercial use of the work;
Under the following conditions: Attribution
· the original author must be given credit;
· for any reuse or distribution, it must be made clear to others what the license terms of this work are;
· any of these conditions can be waived if the authors gives permission.
Statutory fair use and other rights are in no way affected by the above
Main Article Content
Secondary severe thrombocytosis in a patient who underwent splenectomy due to hereditary spherocytosis and its treatment using hydroxyurea
Abstract
Thrombocytosis is a frequently seen condition during childhood. While it usually develops secondarily due to reasons such as infection or anemia, it may rarely develop due to clonal causes. Thrombocytosis becomes a life-threatening condition by causing severe complications such as hemorrhage and thrombosis development. Treatment is not recommended in patients who are asymptomatic and with a platelet count below 1,500,000/mm3, however, treatment is required in cases who are symptomatic and with a platelet count above 1,500,000/mm3 in conditions such as primary thrombocytosis. This article present the outcomes of a patient who was treated using low-dose hydroxyurea when he developed severe thrombocytosis after splenectomy.
